Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Thomson Medical Group Ltd. ( (SG:A50) ) just unveiled an announcement.
TMC Life Sciences Berhad has released its unaudited interim financial report for the financial quarter ended 31 December 2025, providing stakeholders with an early view of its financial performance. The disclosure signals the company’s ongoing reporting discipline and offers investors, regulators, and market watchers updated information that may shape expectations ahead of the full-year audited results.
The most recent analyst rating on (SG:A50) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Thomson Medical Group Ltd. stock, see the SG:A50 Stock Forecast page.
More about Thomson Medical Group Ltd.
TMC Life Sciences Berhad is a Malaysia-incorporated healthcare company operating in the medical and clinical services sector. Based in Petaling Jaya, Selangor, it appears focused on delivering healthcare and related life sciences services in the Malaysian market, supported by its facilities in Kota Damansara.
Average Trading Volume: 6,611,085
Technical Sentiment Signal: Hold
Current Market Cap: S$1.59B
Find detailed analytics on A50 stock on TipRanks’ Stock Analysis page.